CymaBay’s Seladelpar Hits Three Endpoints In Phase III PBC Study

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Seladelpar may threaten an entrenched second-line therapy, Intercept’s Ocaliva, with better efficacy, based on benefits demonstrated in the pivotal RESPONSE trial.

CymaBay Therapeutics, Inc. reported data that analysts called nearly a best-case scenario across three key endpoints for its PPAR delta agonist seladelpar in primary biliary cholangitis (PBC) on 7 September, but a few questions persist about a higher-than-expected placebo response on the Phase III trial’s primary endpoint. Still, the broad expectation is that seladelpar likely will be approved for second-line treatment of PBC and prove strong competition in that setting to Intercept Pharmaceuticals, Inc.’s Ocaliva (obeticholic acid).

Initially, CymaBay was developing seladelpar as one of several PPAR agonists for non-alcoholic steatohepatitis, but missed its primary endpoint of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.